Other · developed by Insmed
ELC is an empty liposome control, a liposome carrier without an active drug payload, given by nebulized inhalation. It is studied in nontuberculous mycobacterial infections, including Mycobacterium avium-intracellulare infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04677543 | Phase 3 | Mycobacterium Infections, Nontuberculous | Completed | INSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mycobacterium Infections, Nontuberculous
Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.
See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INSM catalysts and pipeline →